Medicare Part B Oral Chemotherapy Demo To Cover Tamoxifen and Thalidomide
This article was originally published in The Pink Sheet Daily
Executive Summary
In announcing the start of the demonstration project, CMS departs from earlier demo criteria by saying that tamoxifen qualifies as a “replacement” drug and thalidomide is covered because it has a pending supplemental NDA for an indication qualifying it for the project.